Bank of America lowered its price target for Ultragenyx Pharmaceutical (RARE) from $83 to $76, retaining a "buy" rating.
Bank of America lowered its price target for Ultragenyx Pharmaceutical (RARE) from $83 to $76, maintaining a "buy" rating. The new target indicates a potential upside of 88.40%. The company's Q report had a negative ROE of 425.63% and a negative net margin of 138.58%. RARE's stock traded up $1.69 on Friday, reaching $40.34, with a consensus rating of "Moderate Buy" and an average target price of $91.50.
May 31, 2024
3 Articles